Investor
Every published round Advent took part in, and every parcel of existing shares it bought off another holder. Deals we hold but haven't published yet are not counted.
Companies Advent has backed in a published round, and companies whose existing shares it bought off another holder.
| Company | What it does | First invested | Rounds | Led |
|---|---|---|---|---|
| No portfolio companies recorded yet. | ||||
Fund closes reported for Advent, as distinct from the investments it has made.
Companies Advent has backed that another company then bought. An exit for the holding, not a deal Advent did.
| Company | Bought by | Kind | Announced | Price |
|---|---|---|---|---|
| No portfolio company of Advent is recorded as having been acquired. | ||||
Companies Advent acquired or merged with, per published coverage. Buying a company is not investing in one: nothing here counts in the deals column.
| Company | Kind | Announced | Price | Sources |
|---|---|---|---|---|
| New Zealand Clinical Research Group | Acquisition | 19 Aug 2026 | - | healthcaredealflow.com, biospectrumasia.com, nzcr.co.nz, adventinternational.com, DealStreetAsia |
Stories naming Advent. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Worldwide private equity firm Advent is acquiring a controlling stake in clinical research group NZCR Group; financial terms stay secret, and existing shareholders keep a sizeable minority holding.
Advent International is to take a majority holding in trans-Tasman clinical trials operator NZCR, whose existing backers, among them Waterman Capital, will keep a minority position, with a fourth-quarter close anticipated.
Also adventinternational.com·nzcr.co.nz·biospectrumasia.com·healthcaredealflow.com
Sydney food-and-beverage ordering platform Ordermentum raised $55 million led by Five V Capital, valuing it above $150 million, with some early investors partially exiting.
The ASX-listed energy software firm has turned down Volue's sweetened $17-per-share cash offer worth $539.7 million, calling it opportunistic and undervalued, and pointing to its growth momentum under new chief executive Ben Tranier.
Sydney-based hospitality software company Ordermentum has banked $55m in a Five V Capital deal valuing it above $150m, letting earlier backers sell down; the piece revisits its Foodbomb merger and the investor's other deals.
Growth investor Advent Partners has bought a stake in IT services firm efex, whose founder stays on as CEO; the piece also recalls efex's purchases of Datcom Cloud and Medihost Solutions.
Board change at Sunshine Heart: Nicholas Callinan takes the chairman role at the October 2008 annual meeting as Malcolm McComas steps down from it but stays a director; Callinan's venture capital career is profiled.
Advent International has finished raising its tenth flagship buyout fund, GPE X, hitting a $25 billion hard cap in under six months; with Advent Tech II, combined commitments top $30 billion.
A year after its previous flagship vehicle hit an $11bn ceiling, Apax Partners is chasing a bigger fund, while US pension minutes reveal new commitments and the firm moves to take control of Alcumus.